Recent Updates
Recently added Catalysts

FE203799

Phase 1/2

SBS - Short Bowel Syndrome | Small Molecules | Gastrointestinal |Ironwood Pharmaceuticals, Inc.|Trials Updated: Oct 24, 2024

FE203799 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Jan 2018

FE203799 target and mechanism

ModalitySmall Molecules

Also known as GLP 2 analogue

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment8

FDA Designations

No designations recorded

FE203799 clinical trials

FE203799 · 1 trial · 1 indication

Phase 1/2 1
NCT03408132Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal InsufficiencySBS - Short Bowel Syndrome
COMPLETED8 Analytics
PHASE1/PHASE2COMPLETED
Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency
SBS - Short Bowel SyndromeUnlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of treatment-emergent adverse events
Day -28 to Day 26 plus 6 weeks

Adverse events as assessed by CTCAE v4.03

Secondary Endpoints

Assessment of intestinal insufficiency and gut absorption
Day -28 to day 26
Assessment of gut regeneration
Baseline (Day -7) to end of treatment period (Day 26) plus 6 weeks
Maximum observed plasma concentration (Cmax)
Day 1 to end of treatment period (Day 26)
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeSUPPORTIVE_CARE

Treatment Arms

ArmTypeDescription
FE203799 5 mgEXPERIMENTALFE203799 5 mg subcutaneous injection

Interventions

NameTypeDescription
FE203799DRUGFE203799 5 mg subcutaneous once weekly
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Males and females with SBS secondary to surgical resection of the small intestine, with or without an intact colon. 2. 18-80 years of age 3. Average faecal wet weight excretion of ≥1500 g/day during the baseline balance study 4. Average urine production \<2000 mL/day during t...

Countries:Denmark
Unlock Eligibility Criteria

Competitive Landscape -Short Bowel Syndrome 10 trials (matched to "SBS - Short Bowel Syndrome")

Frequently asked questions about FE203799

What is FE203799?

FE203799 is an investigational small molecule being developed by Ironwood Pharmaceuticals, Inc. for short bowel syndrome (SBS) with intestinal insufficiency. It is in Phase 1 clinical development and has been studied in a single completed trial. It is not described as approved for any use.

What is FE203799 used for in short bowel syndrome?

FE203799 is being developed for short bowel syndrome with intestinal insufficiency, a gastrointestinal condition in which patients have reduced functional intestine. The completed Phase 1 study was a metabolic balance study in patients with SBS with intestinal insufficiency, conducted in Denmark with eight enrolled participants.

Who makes FE203799?

FE203799 is being developed by Ironwood Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker IRWD. Ironwood is the sponsor of the clinical program for this investigational small molecule in short bowel syndrome with intestinal insufficiency.

What phase is FE203799 in?

FE203799 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The program is investigational, and the available information does not indicate that FE203799 has been approved by the FDA or any other regulatory authority.

What clinical trials is FE203799 in?

FE203799 has been evaluated in one completed Phase 1 trial, NCT03408132, titled a metabolic balance study of FE203799 in patients with SBS with intestinal insufficiency. The trial enrolled eight participants in Denmark, included adults 18 years and older of all sexes, and was uncontrolled, without randomization or double blinding.